Somatus Secures $64 Million Series C Funding to Expand Home Dialysis Services Across the U.S.

Recently, VCBeat (WeChat Official Account: vcbeat) learned that Somatus, a comprehensive kidney care services provider, announced the completion of a $64 million Series C financing round. Somatus is an integrated healthcare services company specializing in kidney health management, serving individuals with or at risk of developing kidney disease.

Ikenna Okezie and Anthony Welters co-founded Somatus in 2016. Guided by the health needs of the 300,000 patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) across the United States, the company’s operational philosophy breaks away from traditional kidney care models. It empowers patients to manage their own health while assisting healthcare providers and health insurers in delivering superior health services.

The Origin of the Company Name Somatus

The “so-mat” in the company name is derived from the Latin word “somata,” signifying a healthy body, followed by “us,” representing “we.” Somatus thus metaphorically conveys “our healthy bodies.” Prior to founding Somatus, Ikenna Okezie served on the Medical Review Committee of VCBeat’s Late-Stage Kidney Disease Network and held the position of CEO for DaVita, a dialysis giant, in the Mid-Atlantic region.

During his nearly five-year career in kidney disease health management, Ikenna observed that patient “non-adherence” significantly diminished the effectiveness of disease management programs and increased healthcare system expenditures. With a bachelor’s degree in economics from Yale University and an M.D. from Harvard Medical School, Ikenna immediately recognized the need for innovation in kidney disease management companies. He advocated for developing a patient-centered care model built around individuals with kidney disease, collaborating with healthcare providers and health insurers to serve this population and alleviate the financial burden of kidney disease on the healthcare system.

Anthony Welters, another co-founder of Somatus, boasts an impressive track record in the healthcare industry. In 1989, he founded AmeriChoice, a healthcare company that reached a valuation of $1 billion. He previously served as Executive Vice President and a member of the Office of the CEO at UnitedHealth Group (UHG), where he led UHG’s public and senior markets divisions. Even after his retirement, he continued to serve as a senior advisor to the Office of the CEO at UnitedHealth Group. Through this powerful partnership, Somatus, despite being only four years old, has already emerged as a leader in the kidney health management industry.

Somatus Development Timeline

To date, Somatus has secured a total of $105 million in funding. Its most recent round was a $64 million Series C financing closed this June, which will be used to upgrade its technology and products and expand its operational footprint across the United States. Currently, Somatus provides comprehensive, holistic kidney care services to more than 20,000 patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) in six states. Building on this coverage, Somatus will continue to forge new partnerships and deploy a full suite of kidney health management and dialysis solutions.

SomatusThe company’s remarkable success in the current landscape of chronic kidney disease (CKD) and end-stage renal disease (ESRD) health management is attributable not only to its patient-centric treatment strategy but also to the supportive policies and strategic directions established by U.S. authorities, which have actively propelled the company’s growth.

2019In March, the U.S. Centers for Medicare & Medicaid Services (CMS) announced a reform of the payment framework for kidney disease treatment, aiming to ensure healthy outcomes for patients while controlling costs. The newly released payment structure favors lower-cost home-based care and transplantation, which is poised to disrupt the dialysis industry that provides medical services across thousands of clinics nationwide, thereby creating greater market opportunities for home kidney health care and kidney transplantation.

As early as 2016, when the company was founded, Somatus predicted the development trajectory of the kidney disease treatment market: the future of chronic kidney disease (CKD) management would shift toward home dialysis. Leveraging leader Ikenna Okezie’s experience in kidney health management at DaVita, a dialysis giant, Somatus charted the right course during its early growth phase, enabling its rapid rise. 

In April 2018, Somatus completed an $11 million Series B financing round. This funding helped Somatus expand its market presence while enhancing the capabilities of its technology and service platforms. In 2018, the U.S. Department of Health and Human Services declared kidney disease a priority area, noting that Medicare spending on renal dialysis exceeded the entire budgets of either NASA or the Department of Commerce. This announcement ushered in a golden age of innovation in kidney health management, laying the foundational backdrop for Somatus’s rise.

Under the traditional fee-for-service model, chronic disease management for patients is often inadequate due to untimely communication and a lack of effective incentive mechanisms. Somatus has discarded this business model, revolutionizing chronic kidney disease (CKD) management by integrating renal care services, such as dialysis, with health systems to optimize value for payers.

Somatus’s patient-centric business model not only effectively aligns suppliers and payers in serving patients but also enhances patient engagement in their treatment. Furthermore, leveraging its intelligent technology platform, RenallyQ™, Somatus fully utilizes features such as multi-dataset integration, advanced predictive analytics, and risk stratification to provide comprehensive care solutions for patients with kidney disease.

2017In June, Somatus announced a partnership with Inova Health System, a global leader in personalized health. This collaboration significantly promoted early intervention and kidney disease health education, reducing the incidence of chronic kidney disease. It marked Somatus’s first appearance in the awareness of kidney disease patients since its establishment, receiving widespread acclaim from patients. This initial phase of cooperation preliminarily validated the feasibility of Somatus’s business model. Subsequently, Somatus continued its partnership with Inova, opening more than ten outpatient dialysis centers and establishing collaborations with over 100 local nephrology specialists, thereby laying a solid foundation for future market expansion.

Somatus Historical Financing

Somatus's Core Business: Stages of Kidney Disease Treatment

The kidneys are vital organs in the human body, performing essential functions such as filtering blood and maintaining osmotic pressure. Maintaining kidney health is crucial for the normal functioning of the body. Impaired kidney function can trigger a series of related diseases. Kidney health is classified into five stages based on the degree of functional integrity. Somatus focuses primarily on patient education and interventional treatment for individuals with chronic kidney disease (CKD) and end-stage renal disease (ESRD), aiming to slow the progression of kidney disease.

Traditional kidney disease treatments have often been dialysis-machine-centric, overlooking patients’ own treatment experiences and reducing their adherence to therapy. Somatus remains patient-centered, leveraging its RenallyQ™ intelligent technology platform to provide a range of health management solutions for individuals with chronic kidney disease (CKD) and end-stage renal disease (ESRD). By collaborating with healthcare providers and insurers, Somatus delivers coordinated care and offers patients a novel kidney disease health management experience.

Somatus specializes in providing home dialysis care services, supported by a comprehensive team of physicians, nurses, technical specialists, and dietitians. By extending the duration of home dialysis, this approach preserves residual renal function, significantly slowing the progression of kidney disease. This treatment model not only enhances the patient experience but also buys healthcare providers valuable time to inhibit disease progression, thereby reducing the economic burden on the healthcare system.

Somatus’ innovative kidney disease health management follows a four-step, progressive strategy. The first step focuses on primary objectives: promoting patient health and maintaining normal kidney function through three sub-initiatives—delaying the initiation of dialysis, maximizing the postponement of kidney transplantation, and avoiding dialysis altogether.

Step 2: Establish health education as a cornerstone of the healthcare model. All patients receive education on kidney dialysis, including kidney transplantation as an alternative to lifelong dialysis. Recognizing that learning is a highly personal process, the Somatus team identifies the right professionals to deliver personalized kidney health education tailored to each patient. This educational framework may involve friendly, one-on-one communication with a nurse, technical specialist, dietitian, or nephrologist. Statistics show that Somatus provides kidney health education to 99% of its patients, surpassing the U.S. national average by nearly 70%.

Step three: Somatus coordinates all medical and social health services to streamline the health management experience and reduce the burden of patient care. The company’s proprietary technology platform further enhances these outcomes; its RenallQ™ platform features robust tripartite analytical capabilities that integrate risk, clinical, and financial data, enabling early identification and intervention for both clinical and social needs.

Step 4: To maximize patient convenience, Somatus prioritizes providing dialysis services to patients in home settings. Statistical data show that 35% of Somatus’s patients receive home dialysis, significantly exceeding the national average of 9.7%. Nevertheless, the company has not expanded its home dialysis services. This is primarily because a recent GAO report indicates that established dialysis centers operated by large dialysis organizations have suppressed the economics of home dialysis. The report also points out that Medicare payment policies may hinder the shift toward increased home dialysis services. Despite these challenges, Somatus is the first company committed to delivering both clinical efficacy and convenience to patients. Its ultimate goal is to increase the proportion of patients receiving home dialysis to 50%. Additionally, Somatus has established education and support systems to ensure patients have the confidence to successfully manage home dialysis.

Integrate this innovative philosophy into the company’s operational model to deliver a “four-in-one” kidney disease health management service experience for patients.

Clinical interventions, education, support, and guidance are provided locally by a team of clinicians and surgical experts in the field of nephrology.

Develop and implement value-based strategies and tailored dialysis care approaches based on market dynamics and demographic insights.

Leverage professional expertise, tools, and data-driven insights to drive behavioral change, enhance service quality, and build mutually beneficial partnerships.

The proprietary platform integrates advanced analytics, predictive methodologies, business intelligence dashboards, and clinical workflows to connect vendors, payers, and expert teams, thereby enhancing interventions for kidney disease.

RenalIQ™ Technology is the core of Somatus’s innovative approach to kidney health management. It collects and analyzes data from claims, medical records, and other sources to predict and identify low-cost, high-quality kidney health management services for individuals with or at risk of kidney disease. The platform not only collects and analyzes patient health data but also consolidates health information to enable collaborative vendors, insurers, and expert teams to implement corresponding action plans. These efforts provide patients with assessments of psychosocial and clinical needs, chronic kidney disease education, nutritional and novel social kidney health care services, as well as home-based and post-acute care services.

Deployment for Insurers——The RenallQ™ proprietary technology platform leverages diverse datasets, advanced predictive analytics, and risk stratification to identify distinct high-risk patient populations. By integrating intelligent workflow applications, the platform guides healthcare teams in delivering appropriate interventions and provides actionable recommendations to improve clinical outcomes and program effectiveness.

Deployment of Healthcare Systems——The RenallQ™ proprietary technology platform is dedicated to serving key stakeholders by providing advanced prescriptive and descriptive analytics, as well as solutions for intelligent health care management workflows. It delivers benchmark performance, enables continuous improvement, and drives better outcomes.

Deployment for Suppliers—The RenallQ™ proprietary technology platform breaks free from traditional constraints, enhancing performance transparency, improving decision-making, and advancing patient care. By leveraging multiple datasets to deliver descriptive and explanatory analytics, the platform further enables performance evaluation and advanced predictive analytics, thereby driving cost-effective decision-making. To expand enterprise reach and impact, the platform also provides vendors with care management workflow guidance and patient education tools.

Somatus’s success lies in its close alignment with policy changes in kidney disease health management within the U.S. healthcare system. The founders accurately “anticipated market shifts” and proactively established a patient-centric home dialysis business model, expanding their market presence across the United States through partnerships with leading chronic disease management providers and insurers.

Of course, a strong reputation is built on excellent service. The fact that Somatus has reached approximately 20,000 patients across six U.S. states in just four years speaks volumes about its service quality. Therefore, in the current landscape of mature policies, Somatus has naturally emerged as one of the most promising leaders in kidney health management. Its latest funding round, amounting to $64 million, further demonstrates Somatus’s confidence and capability to make significant strides in the field of kidney health management.

In recent years, cloud-based health management for chronic kidney disease (CKD) has gained significant traction in China. A plethora of healthcare service providers dedicated to CKD patients have emerged, including nephrology specialty clinics, online health education platforms, dialysis centers, and CKD cloud management service providers. Notable examples include Shentai Network, Yinchuan Dakang Yijia Internet Hospital for Nephrology, Ai Shen Internet Hospital, and Ai Shen Medical. Most of these entities are startups operating in a highly competitive landscape, where the ability to identify and capitalize on key aspects of the CKD management market will determine who can establish a firm foothold first.

From Somatus’s entrepreneurial journey, we can see that policy changes determined whether the service guidelines formulated by Somatus were patient-centered, and collaborations with well-known health insurance providers/suppliers influenced whether Somatus could gain patient acceptance in a short period. Beneficial business partnerships greatly contribute to the progress of startups; securing opportunities to emerge from industry-leading enterprises with significant influence may be the most effective shortcut for entering the market and expanding one’s impact.